跳至主要内容
临床试验/CTRI/2021/05/033805
CTRI/2021/05/033805已完成未知

Role of 68gallium-PSMA-11 PET/CT in early response prediction to anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma

Postgraduate Institute of Medical Education and Research0 个研究点目标入组 27 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
27

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Adults = 18 years of age
  • 2. Biopsy proven metastatic Renal Cell Cancer
  • 3. Planned for targeted TKI therapy (first and second line).
  • 4. Life expectancy > 6 months.
  • 5. Patient consent to participate in the study.

排除标准

  • 1. Pregnant or lactating women.
  • 2. Active malignancy other than renal cell cancer.
  • 3. Tyrosine Kinase Inhibitor Therapy (TKI) within 4 weeks prior to enrolment.
  • 4. Patients not giving consent to participate

研究者

相似试验